Lahoria Utkrist, Singh Saurabh, Bhardwaj Abhishek, Budania Anil, Chhajed Neelam, Rajagopal Srinivasan Varun, Singh Surjit
Department of Dermatology, All India Institute of Medical Sciences, Jodhpur, India.
Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.
J Cosmet Dermatol. 2023 Apr;22(4):1400-1409. doi: 10.1111/jocd.15564. Epub 2023 Feb 9.
Interventional, prospective, four arm randomized control.
Outpatient department, Department of Dermatology, Venereology and Leprology, AIIMS Jodhpur (Rajasthan), India.
Two hundred patients.
The intervention administered in the groups were normal saline (A), vitamin D (B), MIP (C), and MMR (D). The injections were given into the largest wart at 2-weekly intervals until complete clearance or for a maximum of seven sittings. Post-treatment clearance of the injected wart and the distant wart was compared on the basis of change in wart number, percentage clearance, and mean time to complete clearance. Side effects were recorded.
A total of 197 patients were recruited. The mean percentage improvement in the injected and non-injected warts was 68.4% and 66.8%, respectively. Intention to treat analysis (ITT) showed that complete clearance of lesions in injected wart occurred in placebo, vit D , MMR, and MIP arms in 64%, 66%, 58%, and 55% patients, respectively (p > 0.05), while in the non-injected warts in 62%, 64%, 52%, and 53%, respectively (p > 0.05). The mean time to achieve complete clearance of wart was fastest in MIP at 7.1 weeks followed by MMR at 7.2 weeks, VIT D at 7.4 weeks and in placebo group 7.8 weeks (p > 0.05). Side effects noted were fever, pain, erythema, and swelling which was highest in VIT D group (p < 0.05).
The efficacy of immunotherapies was comparable to placebo with minimal side effects.
干预性、前瞻性、四臂随机对照试验。
印度拉贾斯坦邦焦特布尔全印医学科学研究所皮肤科、性病科和麻风病科门诊。
200名患者。
各组接受的干预措施分别为生理盐水（A组）、维生素D（B组）、MIP（C组）和MMR（D组）。每隔两周在最大的疣体上注射，直至疣体完全清除或最多注射七次。根据疣体数量变化、清除百分比和完全清除的平均时间，比较注射疣体和远处疣体治疗后的清除情况。记录副作用。
共招募了197名患者。注射疣体和未注射疣体的平均改善百分比分别为68.4%和66.8%。意向性分析（ITT）显示，安慰剂组、维生素D组、MMR组和MIP组中，注射疣体的病变完全清除率分别为64%、66%、58%和55%（p>0.05），而未注射疣体的清除率分别为62%、64%、52%和53%（p>0.05）。MIP组达到疣体完全清除的平均时间最快，为7.1周，其次是MMR组7.2周、维生素D组7.4周，安慰剂组为7.8周（p>0.05）。记录到的副作用有发热、疼痛、红斑和肿胀，其中维生素D组最高（p<0.05）。
免疫疗法的疗效与安慰剂相当，副作用最小。
